RIP1 Cancer Research Results

RIP1, RIPK1, Receptor-Interacting Protein 1: Click to Expand ⟱
Source:
Type:
RIP1 (Receptor-Interacting Protein 1) is a protein kinase that plays a crucial role in cell signaling pathways, including those involved in inflammation, cell death, and cancer.

RIP1 is often overexpressed, and associated with poor prognosis.

RIP1 and RIP3 are key regulators of necroptosis and are involved in intricate signaling pathways that dictate cell survival, inflammation, and death.
Their dual roles in cancer can have opposing effects on tumor progression: while necroptosis may promote anti-tumor immunity and improve outcomes in some contexts, pro-survival signaling mediated by RIP1 can contribute to tumor aggressiveness and resistance to therapy.

RIPK1 (Receptor-Interacting Serine/Threonine-Protein Kinase 1) — Multifunctional serine/threonine kinase and signaling scaffold that regulates cell survival, apoptosis, necroptosis, and inflammatory signaling downstream of receptors including TNFR1 and related death receptors.

Typical modulation in cancer: Context-dependent. RIPK1 can promote tumor-cell survival through scaffold-dependent NF-kB signaling, but its kinase activity can also promote RIPK1-dependent apoptosis or RIPK1/RIPK3-mediated necroptosis. Consequently, RIPK1 activation or inhibition may be beneficial depending on tumor type, pathway state, and treatment context.

Typical mechanistic relationships: TNF/TNFR1 → RIPK1 → NF-kB signaling and cell survival; or, under appropriate conditions, RIPK1 kinase activation → RIPK3 → MLKL phosphorylation/oligomerization → necroptosis. RIPK1 can also participate with FADD and caspase-8 in RIPK1-dependent apoptosis.

Necroptosis relevance: RIPK1 is a major upstream regulator of canonical necroptosis and can form a RIPK1-RIPK3 signaling complex (necrosome) leading to MLKL activation and membrane rupture.



Scientific Papers found: Click to Expand⟱
988- EMD,    Emodin Induced Necroptosis and Inhibited Glycolysis in the Renal Cancer Cells by Enhancing ROS
- in-vitro, RCC, NA
Necroptosis↑, p‑RIP1↑, MLKL↑, ROS↑, Glycolysis↓, GLUT1↓, PI3K↓, Akt↓,
2362- SK,    RIP1 and RIP3 contribute to shikonin-induced glycolysis suppression in glioma cells via increase of intracellular hydrogen peroxide
- in-vitro, GBM, U87MG - in-vivo, GBM, NA - in-vitro, GBM, U251
RIP1↑, RIP3↑, Glycolysis↓, G6PD↓, HK2↓, PKM2↓, H2O2↑, GSH↓, ROS↑,
2197- SK,    Shikonin derivatives for cancer prevention and therapy
- Review, Var, NA
ROS↑, Ca+2↑, BAX↑, Bcl-2↓, MMP9↓, NF-kB↓, PKM2↓, Hif1a↓, NRF2↓, P53↑, DNMT1↓, MDR1↓, COX2/PTGS2↓, VEGF↓, EMT↓, MMP7↓, MMP13↓, uPA↓, RIP1↑, RIP3↑, Casp3↑, Casp7↑, Casp9↑, P21↓, DFF45↓, TRAIL↑, PTEN↑, mTOR↓, AR↓, FAK↓, Src↓, Myc↓, RadioS↑,
2188- SK,    Molecular mechanism of shikonin inhibiting tumor growth and potential application in cancer treatment
- Review, Var, NA
ROS↑, EGFR↓, PI3K↓, Akt↓, angioG↓, Apoptosis↑, Necroptosis↑, GSH↓, Ca+2↓, MMP↓, ERK↓, p38↑, proCasp3↑, eff↓, VEGF↓, FOXO3↑, EGR1↑, SIRT1↑, RIP1↑, RIP3↑, BioAv↓, NF-kB↓, Half-Life↓,
2222- SK,    The anti-tumor effect of shikonin on osteosarcoma by inducing RIP1 and RIP3 dependent necroptosis
- in-vitro, OS, U2OS - in-vitro, OS, 143B - in-vivo, NA, NA
Necroptosis↑, RIP1↑, RIP3↑, OS↑, P53↑,
1342- SK,    RIP1 and RIP3 contribute to shikonin-induced DNA double-strand breaks in glioma cells via increase of intracellular reactive oxygen species
- in-vitro, GBM, NA - in-vivo, NA, NA
RIP1↑, RIP3↑, DNAdam↑, ROS↑, GSH↓,
5100- SK,    Shikonin-induced necroptosis in nasopharyngeal carcinoma cells via ROS overproduction and upregulation of RIPK1/RIPK3/MLKL expression
- vitro+vivo, NPC, NA
TumCP↓, RIP1↑, ROS↑, Necroptosis↑, Casp3↑, Casp8↑, eff↓, TumCG↓,

Showing Research Papers: 1 to 7 of 7

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

GSH↓, 3,   H2O2↑, 1,   NRF2↓, 1,   ROS↑, 6,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

G6PD↓, 1,   Glycolysis↓, 2,   HK2↓, 1,   PKM2↓, 2,   SIRT1↑, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↑, 2,   proCasp3↑, 1,   Casp7↑, 1,   Casp8↑, 1,   Casp9↑, 1,   MLKL↑, 1,   Necroptosis↑, 4,   p38↑, 1,   RIP3↑, 5,   TRAIL↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 2,   EGFR↓, 1,   ERK↓, 1,   mTOR↓, 1,   PI3K↓, 2,   PTEN↑, 1,   RIP1↑, 6,   p‑RIP1↑, 1,   Src↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

DNMT1↓, 1,   FOXO3↑, 1,   Myc↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DFF45↓, 1,   DNAdam↑, 1,   P53↑, 2,  

Cell Cycle & Senescence(tgid=11) ⓘ

P21↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

TumCG↓, 1,   TumCP↓, 1,  

Migration(tgid=13) ⓘ

Ca+2↓, 1,   Ca+2↑, 1,   EMT↓, 1,   FAK↓, 1,   MMP13↓, 1,   MMP7↓, 1,   MMP9↓, 1,   uPA↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   EGR1↑, 1,   Hif1a↓, 1,   VEGF↓, 2,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 1,   MMP↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   NF-kB↓, 2,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   eff↓, 2,   Half-Life↓, 1,   MDR1↓, 1,   RadioS↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 1,   EGFR↓, 1,   Myc↓, 1,  

Functional Outcomes(tgid=23) ⓘ

OS↑, 1,  
Total Targets: 66

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: RIP1, RIPK1, Receptor-Interacting Protein 1
6 Shikonin
1 Emodin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:0  prod#:%  Target#:942  State#:%  Dir#:2
wNotes=0 sortOrder:rid,rpid

 

Home Page